Our Services
Medical Information
Helpful Resources
Published on: 9/22/2026
Solifenacin (brand name Vesicare) is an antimuscarinic prescription medication used to treat overactive bladder, easing urinary urgency, frequent urination, and urge incontinence, and it is also used for neurogenic detrusor overactivity in some children. Common side effects include dry mouth, constipation, blurred vision, headache, dizziness, indigestion, and difficulty emptying the bladder, with less frequent effects such as rapid heartbeat, drowsiness, or confusion in older adults. Dosage limits, drug interactions, and precautions for kidney, liver, heart, and glaucoma conditions differ from person to person, and there are several important details to consider below before starting or continuing this medication. Because bladder symptoms can also stem from infections, prostate changes, medication effects, or other conditions that solifenacin will not fix, taking a free, instant, online symptom check can help you understand what is most likely behind your symptoms. It takes only a few minutes, stays private, and gives you a clearer, better-informed starting point for deciding on next steps with a clinician.
Last reviewed for medical accuracy: 09/22/2026
Solifenacin is a prescription medication commonly prescribed to treat symptoms of an overactive bladder (OAB). People with OAB often experience sudden urges to urinate, frequent trips to the bathroom, and occasional leakage (urge incontinence). Solifenacin belongs to a class of drugs called antimuscarinics, which help calm the bladder muscle, reducing these disruptive symptoms.
Your healthcare provider may suggest solifenacin if you have:
Before prescribing, your doctor will evaluate your medical history, perform a physical exam, and possibly order tests such as a bladder diary or urinalysis.
Solifenacin is available in tablet form, typically in 5 mg and 10 mg strengths. Common dosing guidelines include:
Always follow your doctor’s instructions precisely. Do not stop or change your dose without consulting your provider.
Most people tolerate solifenacin well, but some side effects can occur. These are typically mild to moderate:
Tips to manage these:
While rare, some side effects require immediate medical attention:
Seek prompt medical help if you experience any of these.
Before starting solifenacin, tell your doctor if you have:
Drug interactions can affect solifenacin’s safety and effectiveness. Inform your provider about all medications and supplements you take, especially:
Your doctor may adjust doses or recommend alternatives based on potential interactions.
Most side effects of solifenacin are manageable, but watch for red-flag symptoms:
For mild concerns, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to get personalized guidance. For any life-threatening or serious symptoms, contact emergency services or go to the nearest hospital immediately.
If you’re unsure whether your symptoms are related to solifenacin or another cause, you might find quick reassurance by completing a free, online symptom check, using the doctor approved Ubie Symptom Checker. It’s confidential, easy to use, and can help you decide if you need to see a medical professional.
Solifenacin can offer significant relief for people struggling with overactive bladder symptoms. By reducing sudden urges, frequent trips to the bathroom, and accidental leakage, it may improve daily comfort and confidence. However, like any medication, it carries potential side effects and interactions. Working closely with your healthcare provider ensures you get the greatest benefit with the least risk.
Always discuss any new or worsening symptoms with your doctor, especially if they could be life-threatening or serious. Never stop or change your medication regimen without professional guidance. If in doubt, reach out to your healthcare team for personalized advice.
(References)
* Morales-Olivas FJ, Estañ L. Solifenacin pharmacology. Arch Esp Urol. 2010 Jan-Feb;63(1):43-52. PMID: 20157218.
* Aschenbrenner DS. New Indication for Solifenacin. Am J Nurs. 2020 Sep;120(9):24-25. doi: 10.1097/01.NAJ.0000697620.32538.38. PMID: 32858691.
* Drugs for overactive bladder. Med Lett Drugs Ther. 2023 Mar 20;65(1672):41-45. doi: 10.58347/tml.2023.1672a. PMID: 36897601.
* Jamil MN, Irum S, Islam EU. Comparison Of Solifenacin And Mirabegron For The Treatment Of Overactive Bladder. J Ayub Med Coll Abbottabad. 2023 Apr-Jun;35(2):298-300. doi: 10.55519/JAMC-02-11795. PMID: 37422825.
* He W, Huang G, Cui W, Tian Y, Sun Q, Zhao X, Zhao Y, Li D, Liu X. Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis. Int Braz J Urol. 2023 Sep-Oct;49(5):535-563. doi: 10.1590/S1677-5538.IBJU.2023.0158. PMID: 37506033; PMCID: PMC10482468.
* Jiang Y, Li X, Guo S, Wei Z, Xu S, Qin H, Xu J. Transcutaneous Electrical Stimulation for Neurogenic Bladder After Spinal Cord Injury: A Systematic Review and Meta-Analysis. Neuromodulation. 2024 Jun;27(4):604-613. doi: 10.1016/j.neurom.2023.06.002. Epub 2023 Aug 28. PMID: 37642626.
* Chen H, Zhang Z, Wu S, Zhang D, Zhong X, Liu X, Wei G. Efficacy and Safety of High-Dose Vitamin D Supplementation vs Solifenacin or Standard Urotherapy for Overactive Bladder Dry in Children: A Randomized Clinical Trial. J Urol. 2024 Jan;211(1):26-36. doi: 10.1097/JU.0000000000003763. Epub 2023 Oct 23. PMID: 37871329.
* Hu Y, Zhang H. Efficacy and safety of solifenacin combined with biofeedback in children with overactive bladder. BMC Urol. 2024 Apr 25;24(1):97. doi: 10.1186/s12894-024-01486-9. Epub 2024 Apr 25. PMID: 38664686; PMCID: PMC11044419.
* Chen H, Zhang Z, Zhang Q, Wang C, Liu Z, Ye Z, Wang X, Wang Y, Liu X, Guanghui Wei. Efficacy of high-dose vitamin D supplementation vs. solifenacin or standard urotherapy for overactive bladder dry in children: a secondary analysis of a randomized clinical trial. World J Urol. 2024 Oct 22;42(1):586. doi: 10.1007/s00345-024-05296-4. Epub 2024 Oct 22. PMID: 39436468.
* Abudasser AM. Sertraline-Induced Urine Incontinence. Eur J Case Rep Intern Med. 2025;12(11):005846. doi: 10.12890/2025_005846. Epub 2025 Oct 22. PMID: 41229644; PMCID: PMC12604892.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.